Venetoclax Monotherapy for Relapsed/Refractory MM: Phase I Results

December 3-6, 2016; San Diego, California
Venetoclax was safe and tolerable in heavily pretreated patients with myeloma with an ORR of 40% in patients with t(11;14) translocation.
Format: Microsoft PowerPoint (.ppt)
File Size: 653 KB
Released: December 7, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

On-demand webcast from ProCE and Clinical Care Options (CCO), Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discuss the management of relapsed/refractory multiple myeloma

Rebecca Gonzalez, PharmD, BCOP Bhavesh Shah, RPh, BCOP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: June 15, 2022 Expired: June 14, 2023

DETERMINATION trial: addition of ASCT to VRd followed by lenalidomide maintenance until disease progression, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Preliminary results suggest GC012F confers deep responses in heavily pretreated patients with relapsed/refractory multiple myeloma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings